About

Radiopharmaceutical Specialists

At the CPDC we discover, develop, and distribute radiopharmaceuticals. The CPDC was founded in 2008 as a Centre of Excellence for Commercialization and Research (CECR), specializing in radiopharmaceutical research and development. Since its inception, CPDC has gained recognition as a leading radiopharmaceutical organization. It is one of a very few R&D centres that has the full range of scientific, technical, regulatory and business expertise combined with the full specialized infrastructure required to translate radiopharmaceuticals to the clinic and provide them to the commercial marketplace

CPDC has assembled a superb team comprised of seasoned executives, entrepreneurs, and drug developers to complement its unique and strong foundation of specialized staff that have a depth of scientific, technical, regulatory and market experience. Working with our academic and pharma partners CPDC has completed over 50 radiopharmaceutical discovery, development, and manufacturing programs. We have brought over a dozen radiopharmaceuticals into clinical development, which currently support more than 25 clinical trials in Canada, North America and Europe.

Centre for Probe Development & Commercialization (CPDC) Appoints New CEO and President

Hamilton, Ontario, October 3, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, today is announcing that its founder, Dr. John Valliant, has stepped down from his role as CEO to focus his time as the CEO of Fusion Pharmaceuticals. Dr. Valliant will

CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.

CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.

CPDC’s manufacturing facilities are approved by both Health Canada and the US FDA for the production of positron emitting radiopharmaceuticals.

Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.

During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.

CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.

CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.

Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.

Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.

ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.

Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.